NICE has reversed its stance on UCB and Amgen's severe osteoporosis therapy Evenity, saying out can be prescribed on the NHS for women with the disease in England and Wales who are at high
Amgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that the additional data they have provided will help overcome the FDA’s pre
Understanding complex scientific studies is often a challenge for patients as well as healthcare professionals, but one that may become easier thanks to artificial intelli
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.